Ocular Therapeutix (OCUL) Total Current Liabilities (2013 - 2026)

Ocular Therapeutix's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $47.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 25.73% year-over-year to $47.7 million in Q1 2026; TTM through Mar 2026 was $47.7 million, a 25.73% increase from a year earlier, with the FY2025 full-year figure at $50.8 million, up 22.86% from the prior year.
• Total Current Liabilities eased to $47.7 million in Q1 2026 per OCUL's latest filing, from $50.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $50.8 million in Q4 2025 and bottomed at $24.0 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $34.9 million (2023), against an average of $35.5 million.
• Across the five-year window, Total Current Liabilities decreased 18.23% in 2024 and surged 56.09% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $31.4 million in 2022, then climbed by 11.15% to $34.9 million in 2023, then gained by 18.51% to $41.4 million in 2024, then grew by 22.86% to $50.8 million in 2025, then declined by 6.15% to $47.7 million in 2026.
• Per Business Quant, the three latest OCUL Total Current Liabilities figures stand at $47.7 million (Q1 2026), $50.8 million (Q4 2025), and $49.3 million (Q3 2025).